Cost-effectiveness of incorporating inactivated poliovirus vaccine into the routine childhood immunization schedule

JAMA

Volumn 276, Issue 12, 1996, Pages 967-971

  Miller, Mark A ^a   Sutter, Roland W ^a   Strebel, Peter M ^a   Hadler, Stephen C ^a  

^a CENTERS FOR DIS CONTR AND PREV   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; INACTIVATED VIRUS VACCINE; ORAL POLIOMYELITIS VACCINE; POLIOMYELITIS VACCINE;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; HUMAN; MATHEMATICAL MODEL; POLIOMYELITIS; PRIORITY JOURNAL; VACCINATION;

EID: 0029842751     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.276.12.967     Document Type: Article

References (25)

1. Strebel PM, Sutter RW, Cochi SL, et al. Epidemiology of poliomyelitis in the United States one decade after the last reported case of indigenous wild virus-associated disease. Clin Infect Dis. 1992; 14:568-579.
2. Schonberger LB, Kaplan J, Kim-Farley R, Moore M, Eddins DL, Hatch MV. Control of paralytic poliomyelitis in the United States. Rev Infect Dis. 1984;6(suppl):424-426.
3. Prevots DR, Sutter RW, Strebel PM, Weibel RE, Cochi SL. Completeness of reporting for paralytic poliomyelitis, United States, 1980 through 1991: implications for estimating the risk of vaccine-associated disease. Arch Pediatr Adolesc Med. 1994; 148:479-485.
4. Sutter RW, Prevots R. Vaccine-associated paralytic poliomyelitis among immunodeficient persons. Infections Med. 1994;11:426-438.
5. Nightingale EO. Recommendations for a national policy on poliomyelitis vaccination. N Engl J Med. 1977;297:249-253.
6. Institute of Medicine. An Evaluation of Poliomyelitis Vaccine Policy Options. Washington, DC: National Academy of Sciences; 1988:1-50. IOM publication 88-04.
7. de Quadros CA, Henderson DA. Disease eradication and control in the Americas. Biologicals. 1993;21:335-343.
8. Centers for Disease Control and Prevention. Certification of poliomyelitis eradication - the Americas, 1994. MMWR Morb Mortal Wkly Rep. 1994; 43:720-722.
9. Pan American Health Organization. The certification of wild poliovirus eradication from the Western Hemisphere. Epidemiol Bull. 1994;15:1-3.
10. Centers for Disease Control, Advisory Committee on Immunization Practices. Poliomyelitis prevention: enhanced-potency inactivated poliomyelitis vaccine - supplementary statement. MMWR Morb Mortal Wkly Rep. 1987;36:795-798.
11. Hatziandreu EJ, Palmer CS, Halpern MT, Brown RE. A Cost Benefit Analysis of the OPV Vaccine. Arlington, Va: Battelle, Medical Technology Assessment and Policy Research Program, Centers for Public Health Research and Evaluation; 1994. Final report.
12. National Center for Health Statistics. Part 1, National Health Interview Survey, 1994, [public use data tape]. Washington, DC: US Dept of Health and Human Services, Public Health Service; 1995.
13. Centers for Disease Control. Report No. 93, US Biologic Surveillance, 1987-1990. US Dept of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, 1991.
14. Productivity Loss Tables. In: Haddix AC, Teutsch SC, Shaffer PA, Dunet DO, eds. Prevention Effectiveness: A Guide to Decision Analysis and Economic Evaluation. New York, NY: Oxford University Press; 1996:187-192.
15. Woodin K, Rodewald L, Humiston S, Carges M, Schaffer S, Szilagyi P. Physician and parent opinions: are children becoming pincushions from immunizations? Arch Pediatr Adolesc Med. 1995;149: 845-849.
16. Weibel R, Benor DE. Reporting vaccine-associated paralytic poliomyelitis: concordance between CDC and the National Vaccine Injury Compensation Program. Am J Public Health. 1996;86:734-737.
17. Centers for Disease Control and Prevention. National, state, and urban area vaccine coverage levels among children aged 19-35 months - United States, April 1994-March 1995. MMWR Morb Mortal Wkly Rep. 1996;45:145-150.
18. Centers for Disease Control and Prevention. Lack of evidence for wild poliovirus circulation - United States, 1993. MMWR Morb Mortal Wkly Rep. 1995;43:957-959.
19. Landauer KS, Stickle MA. An analysis of residual disabilities (paralysis and crippling) among 100,000 poliomyelitis patients. Presented at the 35th annual session of the American Congress of Physical and Rehabilitative Medicine; September 8-13, 1957; Los Angeles, Calif.
20. Rice DP, Hodgson TA, Kopgtein AN. The economic costs of illness: a replication and update. Health Care Financing Rev. 1985;7:61-80.
21. Centers for Disease Control and Prevention. Food and Drug Administration Approval of an Acellular Pertussis Vaccine for the Initial Four Doses of the Diphtheria, Tetanus, and Pertussis Vaccination. MMWR Morb Mortal Wkly Rep. 1996;45:676-677.
22. Centers for Disease Control. Vaccination against smallpox in the United States: a reevaluation of the risks and benefits. MMWR Morb Mortal Wkly Rep. 1971;20:339-345.
23. Sencer DJ, Axnick NW. Cost benefit analysis. In: International Symposium on Vaccination Against Communicable Diseases, Monaco, March 14-17, 1973. Symposium Series in Immunobiological Standardization. Basel, Switzerland: S Karger AG; 1973;22:37-46.
24. Lane JM, Millar JD, Neff JM. Smallpox and smallpox vaccination policy. Annu Rev Med. 1971; 22:251-272.
25. Centers for Disease Control. Public Health Service recommendation on smallpox vaccination. MMWR Morb Mortal Wkly Rep. 1971;20:339.